| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.093 | 0.007 |
| mRNA | KIN001-244 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.007 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.008 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.083 | 0.008 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.1 | 0.009 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.093 | 0.009 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.01 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | -0.15 | 0.01 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | -0.082 | 0.01 |